Patients with esophageal cancer that had metastatic lesions after been treated with surgery
or definitive chemoradiotherapy are being asked to participate in this study.
Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine
kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of
vatalanib or sorafenib.
The purpose of this study is to determine what effects apatinib has on metastatic esophageal
cancer. These effects include whether apatinib could shrink the tumor or slow down its growth
and what side effects apatinib will have on the tumor.